We calculated the adjusted hazard ratios (AHRs) (adjusted with age at diagnosis, sex, tumor size, extrathyroidal invasion, lymph node metastasis) for risk of recurrence in each category of DRS with and without BRAF mutation. Here, BRAF is linked to neoplasm.